These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Determinants involved in the affinity of alpha-conotoxins GI and SI for the muscle subtype of nicotinic acetylcholine receptors. Groebe DR; Gray WR; Abramson SN Biochemistry; 1997 May; 36(21):6469-74. PubMed ID: 9174364 [TBL] [Abstract][Full Text] [Related]
23. Molecular Determinants of α3β4 Nicotinic Acetylcholine Receptors Inhibition by Triterpenoids. Eom S; Kim YS; Lee SB; Noh S; Yeom HD; Bae H; Lee JH Biol Pharm Bull; 2018; 41(1):65-72. PubMed ID: 29311484 [TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship and site of binding of polyamine derivatives at the nicotinic acetylcholine receptor. Bixel MG; Krauss M; Liu Y; Bolognesi ML; Rosini M; Mellor IS; Usherwood PN; Melchiorre C; Nakanishi K; Hucho F Eur J Biochem; 2000 Jan; 267(1):110-20. PubMed ID: 10601857 [TBL] [Abstract][Full Text] [Related]
25. [(3)H]chlorpromazine photolabeling of the torpedo nicotinic acetylcholine receptor identifies two state-dependent binding sites in the ion channel. Chiara DC; Hamouda AK; Ziebell MR; Mejia LA; Garcia G; Cohen JB Biochemistry; 2009 Oct; 48(42):10066-77. PubMed ID: 19754159 [TBL] [Abstract][Full Text] [Related]
26. Mutations in the M1 region of the nicotinic acetylcholine receptor alter the sensitivity to inhibition by quinacrine. Tamamizu S; Todd AP; McNamee MG Cell Mol Neurobiol; 1995 Aug; 15(4):427-38. PubMed ID: 8565046 [TBL] [Abstract][Full Text] [Related]
27. Probing the structure of the affinity-purified and lipid-reconstituted torpedo nicotinic acetylcholine receptor. Hamouda AK; Chiara DC; Blanton MP; Cohen JB Biochemistry; 2008 Dec; 47(48):12787-94. PubMed ID: 18991407 [TBL] [Abstract][Full Text] [Related]
28. Site-selective photoaffinity labeling of the Torpedo californica nicotinic acetylcholine receptor by azide derivatives of ethidium bromide. Pedersen SE Mol Pharmacol; 1995 Jan; 47(1):1-9. PubMed ID: 7838117 [TBL] [Abstract][Full Text] [Related]
29. Interaction of lipids and ligands with nicotinic acetylcholine receptor vesicles assessed by electron paramagnetic resonance spectroscopy. Arias HR Methods Mol Biol; 2010; 606():291-318. PubMed ID: 20013404 [TBL] [Abstract][Full Text] [Related]
30. Novel alpha-conotoxins from Conus spurius and the alpha-conotoxin EI share high-affinity potentiation and low-affinity inhibition of nicotinic acetylcholine receptors. López-Vera E; Aguilar MB; Schiavon E; Marinzi C; Ortiz E; Restano Cassulini R; Batista CV; Possani LD; Heimer de la Cotera EP; Peri F; Becerril B; Wanke E FEBS J; 2007 Aug; 274(15):3972-85. PubMed ID: 17635581 [TBL] [Abstract][Full Text] [Related]
31. Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors. Hansen SB; Taylor P J Mol Biol; 2007 Jun; 369(4):895-901. PubMed ID: 17481657 [TBL] [Abstract][Full Text] [Related]
32. The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface. Blanton MP; Xie Y; Dangott LJ; Cohen JB Mol Pharmacol; 1999 Feb; 55(2):269-78. PubMed ID: 9927618 [TBL] [Abstract][Full Text] [Related]
33. Temperature and ionic strength dependence of quinacrine binding and quinacrine displacement elicited by high concentrations of agonists on the nicotinic acetylcholine receptor. Arias HR Arch Biochem Biophys; 1996 Sep; 333(1):1-11. PubMed ID: 8806747 [TBL] [Abstract][Full Text] [Related]
34. Covalent modification of engineered cysteines in the nicotinic acetylcholine receptor agonist-binding domain inhibits receptor activation. McLaughlin JT; Hawrot E; Yellen G Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):765-9. PubMed ID: 7575408 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, in vitro and in vivo studies, and molecular modeling of N-alkylated dextromethorphan derivatives as non-competitive inhibitors of α3β4 nicotinic acetylcholine receptor. Jozwiak K; Targowska-Duda KM; Kaczor AA; Kozak J; Ligeza A; Szacon E; Wrobel TM; Budzynska B; Biala G; Fornal E; Poso A; Wainer IW; Matosiuk D Bioorg Med Chem; 2014 Dec; 22(24):6846-56. PubMed ID: 25464883 [TBL] [Abstract][Full Text] [Related]
36. Binding of polyamine-containing toxins in the vestibule of the nicotinic acetylcholine receptor ion channel. Bixel MG; Krauss M; Weise C; Bolognesi ML; Rosini M; Usherwood PN; Melchiorre C; Hucho F Farmaco; 2001; 56(1-2):133-5. PubMed ID: 11347955 [TBL] [Abstract][Full Text] [Related]
37. Bupropion and its photoreactive analog (±)-SADU-3-72 interact with luminal and non-luminal sites at human α4β2 nicotinic acetylcholine receptors. Arias HR; Feuerbach D; Ortells MO Neurochem Int; 2016 Nov; 100():67-77. PubMed ID: 27612850 [TBL] [Abstract][Full Text] [Related]
38. Characterization of the dizocilpine binding site on the nicotinic acetylcholine receptor. Arias HR; McCardy EA; Blanton MP Mol Pharmacol; 2001 May; 59(5):1051-60. PubMed ID: 11306687 [TBL] [Abstract][Full Text] [Related]
39. Understanding channel blocking in the nicotinic acetylcholine receptor. Ortells MO; Barrantes GE Recept Channels; 2001; 7(4):273-88. PubMed ID: 11697233 [TBL] [Abstract][Full Text] [Related]
40. Selective enhancement of the interaction of curare with the nicotinic acetylcholine receptor. Filatov GN; Aylwin ML; White MM Mol Pharmacol; 1993 Aug; 44(2):237-41. PubMed ID: 8355663 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]